drugset / Trial / NCT04062656
Perioperative Immunotherapy vs. Chemo-immunotherapy in Patients With Advanced GC and AEG
RandomizedParallel-groupOpen-labelTreatment
Summary
IMAGINE is a Phase II, randomized, two-arm, chemotherapy controlled modular trial in subjects with histologically confirmed, resectable gastric cancer (GC) or adenocarcinoma of the gastroesophageal junction (AEG). Up to 22 patients will be included in each arm of the trial.
Timeline
- Start
- 2019-09-26
- Primary completion
- 2024-03
- Completion
- 2025-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nivolumab | Monoclonal antibody | 480 mg | Intravenous |
| Subject | Relatlimab | Monoclonal antibody | 80 mg | Intravenous |
| Background | 5-Fluorouracil (5-FU) | Small molecule | 2600 mg/m2 | Intravenous |
| Background | Docetaxel | Small molecule | 50 mg/m2 | Intravenous |
| Background | Folic acid (FA) | Unknown | 200 mg/m2 | Intravenous |
| Background | Oxaliplatin | Small molecule | 85 mg/m2 | Intravenous |